glp-1 for nash Full article: receptor agonists in the treatment of diabetic non–alcoholic steatohepatitis patients Frontiers | GLP-1 and Underlying

The ACM concluded that the current evidence may support the signal for semaglutide, but not dulaglutide or tirzepatide

Enhancing safety for at-risk patients For people who may be at a higher risk of a fall such as an elderly patient or someone experiencing confusion Telesitter can be an important protective measure during their hospitalization

For those who want the assurance of FDA-approved products, more comprehensive medical oversight, or insurance-covered treatment, traditional healthcare pathways remain the more appropriate choice

In many jurisdictions, including Canada, the protection of a patent can be extended by a certificate of supplementary protection (CSP)